The recent trading activity of key executives provides a focused look into the internal movements within Corcept Therapeutics Inc. (NASDAQ:CORT). Specifically, on June 1, 2026, Mokari Atabak, the company's Chief Financial Officer, executed a sale of 40,000 shares of common stock. The total value realized from this disposition amounted to $2,800,004. These sales were conducted at prices ranging between $70.00 and $70.01 per share.
It is important to note that these transactions were structured under a pre-arranged 10b5-1 trading plan, which Mr. Atabak had adopted on December 12, 2025. Prior to the reported sale, Mr. Atabak had also acquired the same quantity of shares (40,000) on June 1 through the exercise of stock options at a cost of $19.26 per share, representing an acquisition value of $770,400.
Mr. Atabak's activity continued on that date with additional acquisitions. He purchased 634 shares of common stock for $70.44 each through a purchase plan established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan. Furthermore, he received 634 shares classified as unvested restricted stock awards, which had an associated transaction price of $0.00 per share, all stemming from the same Purchase Plan. These restricted shares are conditional, scheduled to vest on the one-year anniversary of the grant date, provided stipulated conditions are met.
The corporate activity continued into June 2, 2026, when 395 shares were disposed of by the company itself. This disposition was necessary to fulfill tax withholding obligations related to the vesting of restricted stock units. These 395 shares were valued at $70.44 apiece, totaling $27,823.
Following all reported transactions, Mr. Atabak's remaining direct ownership stake in Corcept Therapeutics common stock was calculated to be 16,130 shares, a total that includes certain unvested restricted stock awards. While the CFO reduced his immediate position, other market indicators suggest ongoing corporate interest; specifically, InvestingPro Tips indicated that management has been engaged in aggressive share buybacks, which is viewed as a positive signal for current shareholders.
Beyond the reported insider transactions, Corcept Therapeutics provided several critical updates regarding its operational and clinical pipeline. The company reported its first-quarter 2026 earnings, during which revenues reached roughly $164.9 million. This figure represents a 4.9% increase compared to the same period in the previous year.
Despite reporting a net loss of $31.8 million for the quarter, Corcept Therapeutics management raised its full-year revenue guidance. The company now projects revenues to fall between $950 million and $1.05 billion, attributing this elevated optimism primarily to the anticipated successful launch of Lifyorli.
These positive developments were further bolstered by external analysis. H.C. Wainwright responded positively to these reports by increasing its price target for Corcept shares from $65 to $75, while maintaining a Buy rating. Complementing this action, Corcept presented promising data at the ASCO 2026 Annual Meeting. The presentation focused on its Phase 3 ROSELLA trial involving Lifyorli combined with nab-paclitaxel, which demonstrated a 35% reduction in death risk for patients afflicted with platinum-resistant ovarian cancer.
The clinical efficacy metrics presented were detailed: the median overall survival for patients receiving this combination therapy reached 16 months. This figure is compared to 11.9 months recorded for patients who received nab-paclitaxel alone. Additionally, regarding another drug candidate, Corcept plans to resubmit its New Drug Application (NDA) to the FDA for relacorilant. This submission targets treatment for Cushing’s syndrome after the company addressed additional analyses requested by the agency.
H.C. Wainwright reinforced this positive outlook by reiterating a Buy rating and setting a $95 price target for Corcept, specifically based on these detailed clinical advancements. The stock's recent performance reflects this interest, showing a rise to $72.68, which is 9% higher over the past week, contributing to an overall year-to-date gain of 109%. According to InvestingPro analysis, however, the current valuation suggests the stock may be slightly overvalued relative to its determined Fair Value.